Compare UUUU & PRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UUUU | PRAX |
|---|---|---|
| Founded | 1987 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Mining & Quarrying of Nonmetallic Minerals (No Fuels) | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.5B | 9.6B |
| IPO Year | 2006 | 2020 |
| Metric | UUUU | PRAX |
|---|---|---|
| Price | $22.08 | $329.15 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 15 |
| Target Price | $19.92 | ★ $572.13 |
| AVG Volume (30 Days) | ★ 10.2M | 364.5K |
| Earning Date | 01-01-0001 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $65,922,000.00 | N/A |
| Revenue This Year | $70.84 | N/A |
| Revenue Next Year | $51.17 | $6,395.88 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.20 | $26.70 |
| 52 Week High | $27.90 | $354.87 |
| Indicator | UUUU | PRAX |
|---|---|---|
| Relative Strength Index (RSI) | 51.15 | 53.36 |
| Support Level | $19.34 | $290.36 |
| Resistance Level | $23.61 | N/A |
| Average True Range (ATR) | 1.78 | 18.31 |
| MACD | -0.11 | -2.58 |
| Stochastic Oscillator | 63.68 | 56.70 |
Energy Fuels Inc is a United States-based critical minerals company. The Company mines uranium and produces natural uranium concentrates that are sold to nuclear utilities for the production of carbon-free nuclear energy. It holds two of America's key uranium production centers: The White Mesa Mill in Utah, and the Nichols Ranch ISR Facility in Wyoming. It has three reportable segments based on its operations and financial information; Uranium, HMS, and REE.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. It is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company applies genetic insights to the discovery and development of therapies for neurological disorders through two proprietary platforms: Cerebrum and Solidus. It has established a diversified, multimodal CNS portfolio with four clinical-stage product candidates across movement disorders and epilepsy, which include Ulixacaltamide, Relutrigine, Vormatrigine, and Elsunersen. The firm operates in only one segment and is focused on discovering and developing therapies for CNS disorders.